Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of trabectedin in soft tissue sarcoma patients with histological types reported to have chromosomal translocations

Next Previous
Trial Profile

A phase II trial of trabectedin in soft tissue sarcoma patients with histological types reported to have chromosomal translocations

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions

Most Recent Events

  • 07 Oct 2015 New trial record
  • 28 Sep 2015 According to a Taiho Pharmaceutical media release, trabectedin 0.25 mg and 1 mg IV Infusion received marketing approval from the Ministry of Health, Labour and Welfare for the treatment of patients with soft tissue sarcoma in Japan. The results of this and two other trials supported this marketing approval.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top